Laxiriva Med Appelsin/Sitrussmak (Sodium Hydrogen Carbonate, Potassium Chloride, Sodium Chloride, Macrogol 3350)

Macrogol 3350 is a high‑molecular‑weight polymer that retains water in the gut through osmotic pressure. This added water softens the stool, expands its volume, and stimulates peristalsis, facilitating easier passage without directly stimulating intestinal muscles.

The dose of Laxiriva Med is individualized by the prescribing healthcare professional based on the patient’s age, weight, severity of constipation, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Laxiriva Med in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk to the fetus or infant, and under the guidance of a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with stimulant laxatives, Laxiriva Med provides a gentler, water‑based mechanism that is less likely to cause cramping. Unlike bulk‑forming agents, it does not rely on dietary fiber and works quickly by osmotic action, making it suitable for patients needing rapid relief.

Store Laxiriva Med at ambient temperature, preferably below 25 °C. Keep the bottle tightly closed in its original packaging, protect it from moisture and direct sunlight, and discard any product that shows signs of contamination or degradation.

Laxiriva Med is taken orally as a measured dose of the flavored solution. It should be consumed with a glass of water, and the patient should remain well‑hydrated throughout treatment to support its osmotic action.

The most serious risks include severe electrolyte disturbances such as hyponatremia or hyperkalemia, and rare allergic reactions that may present as rash, swelling, or difficulty breathing. Prompt medical attention is required if any of these symptoms occur.

Laxiriva Med should be avoided in individuals with known hypersensitivity to any of its ingredients, in patients with intestinal obstruction, perforation, or severe inflammatory bowel disease, and in those with uncontrolled electrolyte imbalances unless supervised by a physician.